Baxdrostat is primarily investigated for its use in the treatment of treatment-resistant hypertension. It functions as a selective inhibitor of aldosterone synthase, an enzyme involved in the production of aldosterone, a hormone that regulates blood pressure by controlling sodium and potassium balance. By reducing aldosterone levels, baxdrostat helps lower blood pressure in patients who do not respond adequately to standard antihypertensive therapies. Clinical studies have shown that baxdrostat can significantly reduce systolic blood pressure in individuals with resistant hypertension, making it a promising option for managing this high-risk condition. Its targeted mechanism offers potential advantages over broader-acting drugs, with fewer electrolyte-related side effects.